Litigation
Mar. 29, 2016
Jury says Gilead Sciences must pay Merck & Co. $200 million for patent infringement
A federal jury on Thursday said bio-pharmaceutical company Gilead Sciences Inc. has to pay its competitor in the hepatitis C drug market $200 million in damages for infringing on two of Merck & Co.'s patents.




Daily Journal Staff Writer
A federal jury said bio-pharmaceutical company Gilead Sciences Inc. must pay $200 million in damages for infringing on two of its competitor Merck & Co.'s patents, after Gilead forged into the hepatitis C treatment market with blockbuster drugs before getting the legal go-ahead.
New Jersey-based Merck pharmaceuticals was seeking $2 billion in the Northern District case before Judge Jeffrey...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In